Nanoscale Biosensors Steadily Displace MEMS-Scale Devices
Diagnostics developers across major North American and East Asian research markets are increasingly specifying nanoscale biosensors positioned against legacy MEMS-scale sensor designs, responding to demand for single-molecule detection that speeds commercialization without requiring separate laboratory-grade equipment per test at scale. This shift has required vendors to invest in nanofabrication processes and sensitivity testing capability, a process that can take twelve to eighteen months per platform generation given required biocompatibility qualification. Developers are increasingly treating nanoscale capability as a competitive prerequisite for new diagnostics programme launches, accelerating the transition considerably across the industry.
Market Impact: Adds 9 percent biosensor-driven volume








